Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal or liver function

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2349-2358

  Welink, Jan ^a   Boven, Epie ^a   Vermorken, Jan B ^a   Gall, Helen E ^a   Van Der Vijgh, Wim J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LOBAPLATIN; PLATINUM;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LIVER FUNCTION; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CREATININE; CYCLOBUTANES; ERYTHROCYTES; FEMALE; HALF-LIFE; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATELET COUNT; PLATINUM; STEREOISOMERISM;

EID: 0032836901     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Voegeli, R., Schumacher, W., Engel, J., Respondek, J., and Hilgard, P. D-19466, a new cyclobutane-platinum complex with antitumor activity. J. Cancer Res. Clin. Oncol., 116: 439-442, 1990.
2. Harstrick, A., Bokemeyer, C., Scharnofske, M., Hapke, G., Reille, D., and Schmoll, H. J. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother. Pharmacol., 33: 43-47, 1993.
3. Fiebig, H. H., Hens, H., and Mross, K. Phase I clinical trial of lobaplatin (D-19466) after intravenous bolus injection. Onkologie, 17: 142-148, 1994.
4. Meijer, C., Mulder, N. H., Timmer-Bosscha, H., Sluiter, W. J., Meersma, G. J., and de Vries, E. G. E. Relationship of cellular glutathi-one to the cytotoxicity and resistance of seven platinum compounds. Cancer Res., 52: 6885-6889, 1992.
5. Gietema, J. A., Guchelaar, H. J., de Vries, E. G. E., Aulenbacher, P., Sleijfer, D. T., and Mulder, N. H. A Phase I study of lobaplatin (D-19466) administered by 72 h continous infusion. Anticancer Drugs, 4: 51-55, 1993.
6. Gietema, J. A., Veldhuis, G. J., Guchelaar, H. J., Willemse, P. H., Uges, D. R., Cats, A., Boonstra, H., van der Graaf, W. T., Sleijfer, D. T., and de Vries, E. G. E. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br. J. Cancer, 71: 1302-1307, 1995.
7. Kavanagh, J., Edwards, C. L., Freedman, R. S., Finnegan, M. B., Balat, O., Tresukosol, D., Burk, K., Loechner, S., Hord, M., and Franklin, J. L. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol. Oncol., 58: 106-109, 1995.
8. Köhne-Wömpner, C. H., Harstrick, A., and Bachmann, P. Single agent lobaplatin is active in patients with oesophageal squamous cell carcinoma: a Phase II evaluation. Ann. Oncol., 5: 8, 1994.
9. Fiebig, H. H. Phase I and II studies with lobaplatin. In: 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 176. Amsterdam: Free University, 1995.
10. Mross, K., Meyberg, F., and Fiebig, H. H. Pharmacokinetic and pharmacodynamic study with lobaplatin (D-19466), a new platinum complex, after bolus administration. Onkologie, 15: 139-146, 1992.
11. Welink, J., Pechstein, B., and Van der Vijgh, W. J. F. Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultra-violet detection. J. Chromatogr. Biomed. Appl., 675: 107-111, 1996.
12. Heinzel, G., Woloszcak, R., and Thomann, P. TopFit 2.0. Pharmacokinetic and Pharmacodynamic Data Analysis System. New York: Gustav Fischer Verlag/VCH Publishers, 1993.
13. Ratain, M. J., Schilsky, R. L., and Conley, B. A. Pharmacodynamics in cancer therapy. J. Clin. Oncol., 10: 1739-1753, 1990.
14. Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976.
15. Workman, P., and Graham, M. A. Pharmacokinetics and Cancer Chemotherapy, Vol. 17, pp. 58-61. Plainview, NY: CSHL Press, 1993.
16. Van der Vijgh, W. J. F., and Klein, I. Protein binding of five platinum compounds. Cancer Chemother. Pharmacol., 18: 129-132, 1986.
17. Elferink, F., Van der Vijgh, W. J. F., and Klein, I. Pharmacokinetics of carboplatin after i.v. administration. Cancer Treat. Rep., 71: 1231-1237, 1987.
18. Van der Vijgh, W. J. F. Clinical pharmacokinetics of carboplatin. Clin. Pharmacokin., 21: 242-261, 1991.
19. Vermorken, J. B., Van der Vijgh, W. J. F., and Klein, I. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat. Rep., 68: 505-513, 1984.
20. Vermorken, J. B., Van der Vijgh, W. J. F., and Klein, I. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin. Pharmacol. Ther., 39: 136-144, 1986.
21. Calvert, A.H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxal, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., and Wiltsaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 11: 1748-1756, 1989.